6/20/2024  5:36:24 PM Chg. +0.500 Volume Bid6/20/2024 Ask5:36:24 PM Market Capitalization Dividend Y. P/E Ratio
27.300EUR +1.87% 2,372
Turnover: 63,850.700
-Bid Size: - -Ask Size: - 1.61 bill.EUR 0.10% -

Business description

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.

Management board & Supervisory board

Dr. Michael Ramroth
Management board
Ainhoa Mendizabal Zubiaga, Peter Janssen, Dr. Jörg Schüttrumpf
Supervisory board
Dr. Bernhard Ehmer, David Bell, Uta Kemmerich-Keil, Jürgen Heilmann, Dirk Schuck, Raimon Grifols Roura

Company data

Name: Biotest AG
Address: Landsteinerstraße 5,D-63303 Dreieich
Phone: +49-6103-801-0
Fax: +49-6103-801-150
E-mail: mail@biotest.de
Internet: www.biotest.de
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 100.00%
IPO date: 10/14/1987

Investor relations

Name: Dr. Monika Buttkereit
IR phone: +49-6103-801-4406
IR Fax: +49-6103-801-347
IR e-mail: investor_relations@biotest.de

Company calendar

CW 31 | 7/30/2024 Interim Report 2nd Quarter/6 Months
CW 45 | 11/5/2024 Interim Report 3rd Quarter/9 Months

Main Shareholders